Precision therapy for acute myeloid leukemia.

about

Protein kinase inhibitors for acute leukemia.Molecular landscape and targeted therapy of acute myeloid leukemia

P2860

Q49873905-1F3EB2F1-E695-4EDB-92EE-B5D24BA53046 Q59130314-370DC1BB-765D-4BA0-8387-5D3F80E5D180

P2860

Precision therapy for acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q49534332

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Precision therapy for acute myeloid leukemia.

@en

Precision therapy for acute myeloid leukemia.

@nl

type

Item

label

Precision therapy for acute myeloid leukemia.

@en

Precision therapy for acute myeloid leukemia.

@nl

prefLabel

Precision therapy for acute myeloid leukemia.

@en

Precision therapy for acute myeloid leukemia.

@nl

P1476

Precision therapy for acute myeloid leukemia.

@en

P2093

Jianxiang Wang

http://www.w3.org/2001/XMLSchema#string

Xue Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Midostaurin: an emerging treatment for acute myeloid leukemia patients

Chimeric antigen receptor therapy for cancer

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: ...

The blockade of immune checkpoints in cancer immunotherapy

Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification

Immune checkpoint blockade: a common denominator approach to cancer therapy

P2888

s13045-017-0543-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13045-017-0543-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100187506

http://www.w3.org/2001/XMLSchema#string

P698

29301553

http://www.w3.org/2001/XMLSchema#string

P932

5755341

http://www.w3.org/2001/XMLSchema#string

Precision therapy for acute myeloid leukemia.

about

P2860

P2860

Precision therapy for acute myeloid leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932